Tight glucose control: should we move from intensive insulin therapy alone to modulation of insulin and nutritional inputs? by Kalfon, Pierre & Preiser, Jean-Charles
Page 1 of 2
(page number not for citation purposes)
Available online http://ccforum.com/content/12/3/156
Abstract
The report by Chase and coworkers in the previous issue of
Critical Care describes the implementation into clinical practice of
the Specialized Relative Insulin Nutrition Table (SPRINT) for tight
glycaemic control in critically ill patients. SPRINT is a simple,
wheel-based system that modulates both insulin rate and
nutritional inputs. It achieved a better glycaemic control in a
severely ill critical cohort than their previous method for glycaemic
control in a matched historical cohort. Reductions in mortality were
also observed.
In the previous issue of Critical Care, Chase and coworkers
[1] reported on their implementation into clinical practice and
evaluation of the Specialized Relative Insulin Nutrition Table
(SPRINT). This is an improved protocol in the form of a
wheel-based system to control blood glucose levels and
nutritional intakes in intensive care patients, which was
developed a few years ago [2,3].
Blood glucose has become a key biological parameter in
critical care since publication of the study conducted by van
den Berghe and colleagues [4], who demonstrated decreased
mortality in surgical intensive care patients in association with
tight glycaemic control (TGC), based on intensive insulin
therapy. However, two negative studies were recently
reported, which were interrupted early because of high rates
of severe hypoglycaemia, namely the VISEP study [5] and the
as yet unpublished Glucontrol trial. Hence, there is currently
much debate regarding the actual benefits of such a strategy
in intensive care patients in terms of outcomes [6]. It is also
uncertain whether the results of the ongoing multicentre, open
label, randomized controlled trial NICE SUGAR [7] of the
effects of blood glucose management on 90-day all-cause
mortality in a heterogeneous population of intensive care unit
(ICU) patients will resolve remaining concerns about TGC in
the ICU. Included among these concerns is the key issue of
what is the most appropriate algorithm to achieve the desired
blood glucose range.
The major focus of the study conducted by Chase and
colleagues was on the method to achieve a predetermined
blood glucose range by modulating both insulin infusion rate
and nutritional inputs. As with the other reported studies
comparing protocols, efficacy was evaluated by comparison
with historical control patients. However, although the study
reported by Chase and coworkers was conducted with great
care and rigour, it is but another case-control retrospective
comparative study.
Nevertheless, there is a clear need to introduce efficient tools
that will help clinicians and nursing staff to control blood
glucose levels in ICU patients, because hyperglycaemia
superior to 10 mmol/l is no longer considered to be accep-
table. Studies are required to provide clinicians with recom-
mendations on the evaluation and comparison of the various
protocols currently in use or that are soon to become
available [8,9].
Benchmarking of TGC protocols must take in account all the
dimensions of efficiency : performance, risk for severe hypo-
glycaemia, practical aspects (ease of use, training time and
required materials prior to implementation, error rate), inte-
grated continuous monitoring, nursing workload (evaluated on
the mean time between controls). Furthermore the best way to
compare performance is controversial: is it the time with
glucose within a common target range, the hyperglycaemia
index, the recently described glycaemic penalty index [11], or
the variability that would be associated with outcome [12]?
With respect to this efficiency analysis, SPRINT appears to
be effective. This raises the question of whether the efficacy
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results from instructions regarding nutritional intake, allowing
insulin infusion rates to be limited to a level lower than usual,
or from the intrinsic quality of the algorithm used, which is
based on the glucose-insulin regulatory system model
(capturing insulin utilization rate, insulin losses and saturation
dynamics). Also, SPRINT is apparently associated with few
severe hypoglycemia events, which contrasts with the high
rate of severe hypoglycaemic episodes reported in the
second Leuven study [13]. Finally, SPRINT should be
relatively simple to implement in numerous ICUs as a paper-
based protocol, presented in an original form using a wheel,
without need for computational resources.
Weaknesses of SPRINT rest in its inability to monitor
parameters related to the quality of glucose control as
SPRINT is a paper-based protocol. Most importantly, despite
the favourable subjective opinions of care givers, SPRINT
may not reduce workload because it requires measurements
every hour or 2 hours.
Ultimately, evaluation of any TGC protocol must also include
an assessment of its ability to be implemented easily and
safely in another ICU that did not participate in its develop-
ment [14]. The monocentric study of Chase and coworkers
[1] may not ensure the ‘exportability’ of their TGC protocol.
The debate continues about the real benefits of TGC, with
numerous questions being asked. What is the optimal target
range? Which patients will benefit the most? When during
the ICU stay should TGC be applied and to derive which
benefits? Which is the best method to control glucose level -
intensive insulin therapy, and/or limitation of nutritional intakes
during acute phase, and/or antidiabetic drugs? However, the
competition to develop the ideal tool with which to control
blood glucose levels in the ICU and perhaps throughout the
hospital stay has begun, involving multidisciplinary teams of
physicians and engineers who have specialized in control
systems (feedback control or model predictive control [15]).
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